Cocrystal Pharma Interest Expense 2011-2026 | COCP

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Cocrystal Pharma

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	2 K	4 K	8 K	19 K	58 K	-7 K	1.55 M	-11.4 M	5.65 M	-3.34 M	-5.23 M	-1.24 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
5.65 M	-11.4 M	-1.16 M

Quarterly Interest Expense Cocrystal Pharma

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-220 K	-	-320 K	-140 K	-	-	1 K	1 K	1 K	-	1 K	2 K	1 K	-	2 K	2 K	2 K	-	5 K	5 K	4 K	-	55 K	55 K	32 K	-152 K	150 K	198 K	573 K	-762 K	13 K	977 K	1.32 M	-1.38 M	3.08 M	1.25 M	14.4 M	-	50 K	-	-	-	-992 K	-482 K	-475 K	-	-483 K	-1.01 M	-3.47 M	-	-283 K	-109 K	-110 K

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
14.4 M	-3.47 M	294 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Regeneron Pharmaceuticals REGN	1.7 B	$ 742.1	-1.93 %	$ 77.6 B	USA
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
AbbVie ABBV	2.89 B	$ 211.9	0.37 %	$ 375 B	USA
Replimune Group REPL	-202 K	$ 7.26	-3.71 %	$ 585 M	USA
AbCellera Biologics ABCL	-2.71 M	$ 3.28	-2.24 %	$ 980 M	Canada
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Rigel Pharmaceuticals RIGL	3.71 M	$ 26.28	-0.34 %	$ 473 M	USA
Aileron Therapeutics ALRN	48 K	-	10.36 %	$ 9.8 M	USA
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
Arena Pharmaceuticals ARNA	4.16 M	-	-6.81 %	$ 3.04 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
Avidity Biosciences RNA	-1.94 M	$ 13.07	-0.23 %	$ 1.8 B	USA
Atreca BCEL	3 K	-	-11.76 %	$ 5.79 M	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
bluebird bio BLUE	16.4 M	-	-	$ 546 M	USA
Rhythm Pharmaceuticals RYTM	1.26 M	$ 77.56	-5.31 %	$ 5.04 B	USA
Avid Bioservices CDMO	4.34 M	-	-	$ 789 M	USA
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Adaptive Biotechnologies Corporation ADPT	11.8 M	$ 12.27	-12.11 %	$ 1.86 B	USA
BeiGene, Ltd. BGNE	-42.6 M	-	0.49 %	$ 251 B	Cayman-islands
SIGA Technologies SIGA	3.02 M	$ 5.36	7.96 %	$ 383 M	USA
SELLAS Life Sciences Group SLS	525 K	$ 4.47	-9.69 %	$ 487 M	USA
BioDelivery Sciences International BDSI	-6 K	-	-4.8 %	$ 255 M	USA
Cara Therapeutics CARA	3.59 M	-	-3.03 %	$ 260 M	USA
ChemoCentryx CCXI	2.7 M	-	-	$ 3.74 B	USA
Enlivex Therapeutics Ltd. ENLV	874 K	$ 1.08	-1.38 %	$ 22.2 M	Israel
Enochian Biosciences ENOB	122 K	-	-	$ 40.5 M	USA
Summit Therapeutics SMMT	-53 K	$ 16.59	-3.88 %	$ 12.4 B	Britain
Spruce Biosciences SPRB	90 K	$ 62.07	-10.19 %	$ 47.6 M	USA